Artivion
Builds devices, sealants, valves, and preservation services for cardiac and vascular surgery.
Something off on this page? Send us feedback.
Profile
Sells aortic stent grafts, On-X mechanical valves, surgical sealants, and cryopreserved human tissues through medical-device and preservation-services segments. The business is global, but execution centers on surgeon adoption, regulatory approvals, and recently acquired arch-repair systems.
Combines aortic stent grafts, On-X mechanical valves, BioGlue surgical sealants, and cryopreserved cardiac and vascular allografts. Medical Devices is the larger segment, while Preservation Services keeps the CryoLife tissue base inside the portfolio.
Sells through an international network with manufacturing and operating sites in Georgia, Texas, and Germany. The product mix has shifted toward acquired aortic repair platforms, including JOTEC grafts, Ascyrus AMDS, and Endospan's NEXUS system.
Execution depends on surgeon adoption, quality-controlled tissue processing, approvals for specialized cardiovascular devices, and competition from larger device makers. Recent arch-repair additions make commercialization of NEXUS, AMDS, and ARCEVO LSA a structural dependency.
Company facts
Categories
Key statistics
Year to date −39.9% · Average volume (30d) 685.5K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Canaccord Genuity | Reiterate | Buy | $39 | $40 | |
| Aug 7, 2026 | Canaccord Genuity | Target | $36 | $39 | ||
| Jun 16, 2026 | Canaccord Genuity | Reiterate | Buy | $51 | $36 | |
| Jun 1, 2026 | Stifel Nicolaus | Target | $55 | $45 | ||
| Apr 10, 2026 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.00 | −$0.28 | — | $120.0M | $125.8M | +4.8% | +2.07% |
| May 7, 2026Q1 FY26 | $0.06 | $0.08 | +33.3% | $115.7M | $116.3M | +0.6% | −28.26% |
| Feb 12, 2026Q4 FY25 | $0.14 | $0.17 | +21.4% | $116.5M | $116.0M | −0.4% | −9.96% |
| Nov 6, 2025Q3 FY25 | $0.14 | $0.16 | +14.3% | $116.4M | $113.4M | −2.6% | −5.54% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $99.0M | $113.0M | $113.4M | $116.0M | $116.3M | $125.8M | |
| Gross profit | $63.6M | $73.1M | $74.4M | $69.7M | $71.5M | $80.5M | |
| Operating income | $2.1M | $8.4M | $12.5M | $7.2M | $7.5M | −$8.4M | |
| Net income | −$505.0K | $1.3M | $6.5M | $2.4M | $1.4M | −$13.5M | |
| Diluted EPS | −$0.01 | $0.03 | $0.13 | $0.05 | $0.03 | −$0.28 | |
| Gross margin | 64.2% | 64.7% | 65.6% | 60.1% | 61.5% | 64.0% | |
| Operating margin | 2.2% | 7.4% | 11.1% | 6.2% | 6.4% | -6.7% |
Fiscal years (4-quarter sums)FY21 $298.8M · FY22 $313.8M · FY23 $354.0M · FY24 $388.5M · FY25 $441.3M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $77.3M · Total debt $408.0M · Total assets $1.07B · Shareholders' equity $445.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 48.54M · Float 46.07M · 94.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.98M | 12.70% | 13G | Oct 17, 2025 |
| Nomura Asset Management International Inc. | 2.61M | 5.50% | 13G | Feb 17, 2026 |
| FMR LLC | 2.29M | 5.40% | 13G | Aug 6, 2025 |
| James P. Mackin · officer: President & CEO | 877.3K | 1.81% | Form 4 | Aug 20, 2026 |
| John E. Davis · officer: Chief Commercial Officer | 230.8K | 0.48% | Form 4 | Mar 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | James P. Mackin | officer: President & CEO | −70,000 | $28.96 |
| Aug 14, 2026 | Lance A. Berry | officer: EVP, COO, CFO & Treasurer | −715 | $28.55 |
| Aug 14, 2026 | Andrew M. Green | officer: SVP, Regulatory and Quality | −616 | $28.55 |
| Aug 12, 2026 | Jean F. Holloway | officer: SVP, General Counsel | −977 | $28.49 |
| Jun 11, 2026 | Andrew M. Green | officer: SVP, Regulatory and Quality | −44,001 | $20.70 |
Peers
- Medtronic
Broad overlap in aortic stent grafts and surgical valves
- Edwards Lifesciences
Structural-heart rival in surgical valves, conduits, and patches
- Abbott
Mechanical and tissue valve competitor in cardiac surgery
- BD
Vascular sealant overlap in aortic and vascular surgery
- Baxter International
Adjunctive hemostat and cardiovascular sealant competitor
- LeMaitre
Vascular patch and reconstruction competitor
- Elutia
Cardiovascular biomatrix and tissue-repair competitor
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Artivion | $26.77 | +0.11% | $1.30B | — | 80.9 | 2.8 | +11.3% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Edwards Lifesciences | $91.14 | +1.04% | $51.94B | 51.8 | 28.7 | 8.0 | +13.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Baxter International | $26.30 | +0.65% | $13.51B | — | 12.5 | 1.2 | +5.3% |
| LeMaitre | $80.45 | −0.01% | $1.84B | 28.2 | 26.3 | 7.0 | +9.6% |
| Elutia | $0.8800 | −0.18% | $38.9M | 0.9 | — | 3.2 | −61.3% |
| Median | 32.2 | 17.3 | 3.2 | +9.6% |